Company / Operating Cash Flow per Share
Fulgent Genetics, Inc. Operating Cash Flow per Share History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Cash Flow per Share
-$3.30
FY2025
5-year range
-$3.30 / $18.30
FY2021-FY2025
Trend
-564.0%
vs FY2024
Sector context
#156 of 161
Health Care
What the data says
Operating Cash Flow per Share changed -564% YoY in FY2025, a notable deviation from the 9-year average annual change of +2169%.
Based on SEC 10-K filings.
-3.30 in FY2025.
Declined from $18.30 to $-3.30 over the past 2 years.
Health Care sector context is included.
Operating Cash Flow per Share over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
Bottom 3% in Health CareTop 97% of 161This company -$3.30 Sector average $6.64
▼
-149.6% below sector average
Key checks
Key Insights
- In FY2025, operating cash flow per share decreased 564.0% year-over-year.
- Ranks #156 out of 161 companies in the Health Care sector.
- Peak operating cash flow per share was recorded in FY2023.
Company context
Key Data Points
- Altman Z-Score 5.28 (safe zone, above 2.9 threshold)
- Negative profit margin: -15.1%
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating Cash Flow per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$3.30 | -564.0% |
| FY2024 | $0.71 | -96.1% |
| FY2023 | $18.30 | +292.4% |
| FY2022 | $4.66 | +2281.5% |
| FY2021 | $0.20 | -97.0% |
| FY2020 | $6.55 | +17722.8% |
| FY2019 | -$0.04 | -149.8% |
| FY2018 | $0.07 | -1.0% |
| FY2017 | $0.08 | +130.3% |
| FY2016 | -$0.25 | -204.0% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026